{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "go:GO:0006954",
      "entity_text" : "inflammation",
      "entity_type" : "bioprocess"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:5291",
      "entity_text" : "imatinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Globally, in vitro and in vivo experiments demonstrate that imatinib possesses antiplatelet activity, hypolipidemic and hypoglycemic effects, and inhibits inflammation and atherosclerosis development in several cell types (i.e., decreases of inflammatory cell and VSMC functions and increased vascular permeability).",
  "reading_complete" : "2020-08-03T15:04:00Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:02:12Z",
  "trigger" : "inhibits",
  "evidence" : [ "imatinib possesses antiplatelet activity, hypolipidemic and hypoglycemic effects, and inhibits inflammation" ],
  "pmc_id" : "6524858",
  "score" : 0
}